← Nuvation Bio Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Net loss | ($3.1m) | ($86.8m) | ($104.2m) | ($75.8m) | ($567.9m) | ($204.6m) | — | |
| Net loss on disposal of property and equipment | — | $0 | $50k | $10k | $229k | $33k | — | |
| Depreciation and amortization | $103k | $184k | $199k | $222k | $683k | $1.7m | $2.1m | |
| Amortization of issuance costs | — | — | — | — | $0 | $662k | — | |
| Amortization of premium and discounts on marketable securities | — | — | $3.7m | ($12.1m) | ($9.0m) | ($5.3m) | — | |
| Stock-based compensation | $2.2m | $9.3m | $16.3m | $19.5m | $32.3m | $35.9m | $35.5m | |
| Accounts receivable | — | — | — | $0 | ($12.7m) | ($3.4m) | ($25.0m) | |
| Inventory | — | — | — | — | $0 | ($11.4m) | ($19.3m) | |
| Accounts payable | $34k | $1.9m | ($1.8m) | $70k | ($1.7m) | $3.1m | ($9.8m) | |
| Accrued expenses | $2.9m | $7.5m | ($2.3m) | ($23k) | $6.8m | $12.3m | $22.6m | |
| Prepaid expenses and other current assets | ($339k) | ($2.4m) | ($177k) | $2.3m | ($3.0m) | ($4.3m) | — | |
| Net cash used in operating activities | ($701k) |
($68.2m)
-9629.95%
|
($96.1m)
-40.94%
|
($68.0m)
+29.25%
|
($130.4m)
-91.79%
|
($173.4m)
-32.98%
|
($120.5m)
+30.51%
|
|
| Purchases of property and equipment | ($145k) | ($282k) | ($370k) | ($69k) | ($162k) | ($354k) | ($8.4m) | |
| Realized loss (gain) on marketable securities | — | — | $1.2m | $139k | $12k | ($5k) | — | |
| Interest receivable on marketable securities | ($264k) | ($1.9m) | $554k | ($1.2m) | $132k | $285k | — | |
| Purchases of marketable securities | ($143.3m) | ($609.3m) | ($520.3m) | ($703.4m) | ($339.6m) | ($354.4m) | — | |
| Proceeds from sale of marketable securities | $70.6m | $154.9m | $584.1m | $712.3m | $450.1m | $462.3m | — | |
| Net cash provided by investing activities | ($143.8m) | ($454.7m) | $63.5m | $8.9m | $122.7m | $99.5m | ($47.2m) | |
| Proceeds from borrowings, net of issuance costs | — | — | — | $0 | $12.6m | $60.1m | — | |
| Payments on borrowings | — | — | — | $0 | ($17.2m) | ($11.9m) | — | |
| Payments on debt issuance costs | — | — | — | — | $0 | ($6.6m) | — | |
| Proceeds from issuance of common stock under ESPP | — | $308k | $388k | $253k | $427k | $1.3m | — | |
| Issuance of common stock related to the AnHeart acquisition | — | — | — | $0 | $89.3m | $0 | — | |
| Net cash provided by financing activities | $145.4m |
$625.5m
+330.33%
|
$1.3m
-99.79%
|
$628k
-52.68%
|
$331k
-47.29%
|
$202.5m
+61088.82%
|
$179.1m
-11.55%
|
|
| Cash and cash equivalents, beginning of the period | $29.8m | $132.4m | $101.1m | $42.6m | $35.7m | $164.1m | — | |
| Effect of foreign exchange rate changes on cash and cash equivalents | — | — | — | $0 | $453k | ($265k) | — | |
| Additional Supplementary Disclosures | ||||||||
| Additional Supplementary Disclosures | ||||||||
| Non-cash lease expense | — | $184k | $285k | ($67k) | ($172k) | $275k | — | |
| Non-cash interest on revenue interest financing agreement | — | — | — | — | $0 | $10.1m | — | |
| Change in fair value of warrant liability | $0 | ($4.2m) | ($10.2m) | ($497k) | $936k | $812k | — | |
| Unrealized foreign currency transaction loss | — | — | — | — | $0 | ($1.1m) | — | |
| Acquired in-process research and development | — | — | — | $0 | $425.1m | $0 | — | |
| Other non-current assets | — | — | $0 | ($587k) | ($6.0m) | ($846k) | — | |
| Contract liabilities | — | — | — | $0 | $3.9m | ($7.9m) | — | |
| Cash acquired from AnHeart acquisition | — | — | — | $0 | $19.9m | $0 | — | |
| Transaction costs related to AnHeart acquisition | — | — | — | $0 | ($7.4m) | $0 | — | |
| Cash paid for capitalized market approval intangibles | — | — | — | — | $0 | ($8.0m) | — | |
| Proceeds from revenue interest financing agreement | — | — | — | — | $0 | $150.0m | — | |
| Payments on Finance Agreement | — | — | — | — | $0 | ($493k) | — | |
| Proceeds from exercises of options | — | $450k | $939k | $375k | $4.5m | $10.1m | — | |
| Net decrease in cash and cash equivalents | $26.3m | $102.7m | ($31.3m) | ($58.5m) | ($6.9m) | $128.4m | — | |
| Cash paid for interest | — | — | — | $0 | $341k | $2.9m | — | |
| Cash paid for tax | — | — | — | $0 | $373k | $197k | — | |
| Right-of-use asset recognized | — | $3.9m | $2.2m | $1.2m | $620k | $3.9m | — | |
| Operating lease liability recognized | — | — | — | $1.2m | $608k | $3.9m | — | |
| Issuance of convertible preferred stock related to the AnHeart acquisition | — | — | — | $0 | $274.9m | $0 | — | |
| Issuance of warrants related to the AnHeart acquisition | — | — | — | $0 | $764k | $0 | — | |
| Issuance of replacement awards related to the AnHeart acquisition | — | — | — | $0 | $24.8m | $0 | — |